Robert Wild to Estrogens, Conjugated (USP)
This is a "connection" page, showing publications Robert Wild has written about Estrogens, Conjugated (USP).
Connection Strength
0.614
-
Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS). Menopause. 2021 07 26; 28(10):1108-1116.
Score: 0.191
-
Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 2021 05 03; 28(6):610-618.
Score: 0.188
-
Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013 Mar; 20(3):254-60.
Score: 0.106
-
The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Menopause. 2023 01 01; 30(1):28-36.
Score: 0.052
-
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998 May 13; 279(18):1445-51.
Score: 0.038
-
Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol. 1994 Dec; 84(6):987-95.
Score: 0.030
-
Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group. Climacteric. 1998 Mar; 1(1):26-32.
Score: 0.009